Navigation Links
Spherix Announces the Closing of $6.3 Million Registered Direct Offering
Date:11/19/2009

oduct candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of Naturlose, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to develop Naturlose may be unsuccessful, our common stock could be delisted from the Nasdaq Capital Market, and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our current report on Form 8-K filed on October 10, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

SOURCE Spherix Incorporated


'/>"/>
SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Announces Results of Annual Shareholders Meeting
2. Spherix Incorporated Announces Annual Shareholders Meeting Date
3. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
4. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
5. Spherix Reports Second Quarter 2009 Earnings
6. Spherix Announces Termination of Arla License Agreement
7. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
8. Spherix Regains Full NASDAQ Compliance
9. Spherix to Exhibit at the BIO 2009 International Convention
10. Spherix Recruiting New Independent Director to Regain NASDAQ Compliance
11. Spherix Incorporated Announces the Death of A. Paul Cox, Jr., Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Mapp Biopharmaceutical,s valiant effort to produce ... fight the Ebola outbreak will make the public ... of pharmaceuticals can be, according to Kalorama Information.  ... some may be taken aback by the three-month ... knowledge are well aware of the complex issues ...
(Date:10/20/2014)... Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or ... brings Q3 orders to $5.8 million and provides a good start ... North America and one in the ... new projects at record levels," said Peter Bruijns , President ... the end of Q3 than they have been for any complete ...
(Date:10/20/2014)... BOSTON , Oct. 20, 2014 ... commercialization company tackling big healthcare problems, announced today ... investment round, with participation from Invesco Perpetual, a ... be used to drive PureTech,s existing pipeline forward ... technologies. "PureTech has the scientific creativity to really ...
(Date:10/20/2014)... 2014 Local veterinary surgeon, Dr. Tim ... study of donor stem cells for dogs with osteoarthritis. ... and has performed clinical stem cell therapy for 7 ... determine if a single injection of donor stem cells ... reduce pain and inflammation in the treated joints. ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... Oct. 30 Cephalon, Inc. (Nasdaq:,CEPH) today announced that ... held on,November 5, 2008, will be webcast live on ... ., Cephalon,s senior management will review the company,s ... will be delivered on Wednesday, November 5, 2008 beginning ...
... - Cytochroma today announced the,appointment of Ulrik Spork to ... on the Company,s Board and replaces Dr. Soren Schifter,who ... remains unchanged at,six members., "We are very pleased ... to drawing on his expertise and experiences as we ...
... Discuss Continued Expansion of DXL(TM) Patent Protection at ... 7th Annual BIO ... InNexus,Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX VENTURE: IXS;, http://www.ixsbio.com ... antibodies based on its Dynamic Cross Linking,(DXL(TM)) technology, announced today ...
Cached Biology Technology:Cephalon, Inc. to Webcast Analyst Day 2Cephalon, Inc. to Webcast Analyst Day 3InNexus Biotechnology Receives Patent Grants in Europe 2
(Date:10/16/2014)... human body. Battles are won, lost or sometimes ... stalemate—known as tumor dormancy—can last up to 25 ... is poorly understood. , A new computational ... a Professor of Chemistry at Princeton University, may ... the switch to a malignant state. Published today ...
(Date:10/16/2014)... monocultures can be cultivated efficiently, they are anything ... caused by monoculture cultivation is becoming increasingly evident. ... crop form and are regarded as the sole ... – quite wrongfully, finds Bernhard Schmid, an ecology ... a novel form of agriculture and forestry. After ...
(Date:10/15/2014)... WASHINGTON, N.Y. , Oct. 15, 2014 /PRNewswire/ ... technology solutions for home and community-based care, today ... benefits of implementing Sandata,s Santrax® Electronic Visit Verification™ ... Care Services is a home health company founded ... Texas . The ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
... The Translational Genomics Research Institute (TGen) provides Arizona with ... to the results of an independent analysis released today. ... TGen-led research, a study by the research firm Tripp ... to $321.3 million by 2025. "As we make ...
... September 28, 2009 -- Soybeans contain high ... have antioxidant properties. These molecules can be used ... specific health-beneficial properties and can be used in ... in four forms (α, β, γ, and δ) ...
... biology continue to develop as two of the most ... that the public is almost completely unaware of the ... American adults conducted by Peter D. Hart Research Associates ... 90 percent of Americans think the public should be ...
Cached Biology News:TGen provides Arizona with $77 million in annual economic impact 2TGen provides Arizona with $77 million in annual economic impact 3Eat soybeans to prevent diseases 2Nanotechnology and synthetic biology: What does the American public think? 2
... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
... microscope is described by end-users to be ... the fundamentals of light microscopy and electronic ... footprint, it does not require much space ... busy lab environment. The DM-BA300 combines Motic's ...
... The TUNEL-based assay kit provides complete ... cells for convenient detection of DNA ... sections. The incorporation of BrdU in ... biotinylated or digoxigenylated methods. Results can ...
... ergonomic microscopes are now available in digital ... DM-BA200 comes packed with Motic's patented Colour ... plug and play digital image capture head. ... a reversed quadruple nosepiece, deliver high quality ...
Biology Products: